Research Article
The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer
Figure 2
ROC curves for CEA (a) and CA19-9 (b) were compared with RECIST standards to determine the cut-off values for effective cetuximab treatment.
(a) |
(b) |